Prevention of vomiting, Reflux esophagitis, Diabetic gastric stasis

GI Prokinetic Drugs

Hypersensitivity (eg, laryngeal and glossal angioedema, bronchospasm) to metoclopramide or any component of the formulation; situations where stimulation of gastrointestinal (GI) motility may be dangerous, including mechanical GI obstruction, perforation, or hemorrhage (except when used prior to endoscopy for evaluation of acute upper GI bleeding [Barkun 2010]); pheochromocytoma or other catecholamine-releasing paragangliomas; seizure disorder (eg, epilepsy); history of tardive dyskinesia or dystonic reaction to metoclopramide; concomitant use with other agents likely to increase extrapyramidal reactions.

Pregnancy Category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women; OR animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Drowsiness, fatigue, lassitude, dizziness, confusion, Extrapyramidal symptoms, and Hyperprolactinemia

Adults: Usually 2 ml per dose, 1 to 2 times daily via intramuscular (IM) or intravenous (IV) injection.

Infants under 1 year of age: A single dose of 0.1 mg/kg per body weight, up to a maximum of twice daily. Children: Depending on age, body weight, and symptoms, 1 to 2 times daily via intramuscular (IM) or intravenous (IV) injection.

CrCl >60 mL/minute: No dosage adjustment necessary. CrCl >10 to 60 mL/minute: Administer ~50% of usual total daily dose. CrCl ?10 mL/minute: Administer ~33% (or less) of usual total daily dose.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling 安定性：Store below 25°C, protect from light.